Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study

Background: Iodinated and gadolinium-based contrast media (ICM; GBCM) induce immediate hypersensitivity (IH) reactions. Differentiating allergic from non-allergic IH is crucial; allergy contraindicates the culprit agent for life. We studied frequency of allergic IH among ICM or GBCM reactors.

Methods: Patients were recruited in 31 hospitals between 2005 and 2009. Clinical symptoms, plasma histamine and tryptase concentrations and skin tests were recorded. Allergic IH was diagnosed by intradermal tests (IDT) with the culprit CM diluted 1:10, "potentially allergic" IH by positive IDT with pure CM, and non-allergic IH by negative IDT.

Findings: Among 245 skin-tested patients (ICM = 209; GBCM = 36), allergic IH to ICM was identified in 41 (19.6%) and to GBCM in 10 (27.8%). Skin cross-reactivity was observed in 11 patients with ICM (26.8%) and 5 with GBCM (50%). Allergy frequency increased with clinical severity and histamine and tryptase concentrations (p < 0.0001). Cardiovascular signs were strongly associated with allergy. Non-allergic IH was observed in 152 patients (62%) (ICM:134; GBCM:18). Severity grade was lower (p < 0.0001) and reaction delay longer (11.6 vs 5.6 min; p < 0.001). Potentially allergic IH was diagnosed in 42 patients (17.1%) (ICM:34; GBCM:8). The delay, severity grade, and mediator release were intermediate between the two other groups.

Interpretation: Allergic IH accounted for < 10% of cutaneous reactions, and > 50% of life-threatening ones. GBCM and ICM triggered comparable IH reactions in frequency and severity. Cross-reactivity was frequent, especially for GBCM. We propose considering skin testing with pure contrast agent, as it is more sensitive than the usual 1:10 dilution criteria.

Citing Articles

Acute adverse reactions after multiple initially well-tolerated gadolinium-based contrast-enhanced abdomen MRIs in pediatric patients.

Hojreh A, Mulabdic A, Heilos A, Peyrl A, Lampichler K, Raudner M PLoS One. 2024; 19(12):e0313495.

PMID: 39625932 PMC: 11614221. DOI: 10.1371/journal.pone.0313495.

How to Define and Manage Low-Risk Drug Allergy Labels.

Copaescu A, Li L, Blumenthal K, Trubiano J J Allergy Clin Immunol Pract. 2024; 12(5):1095-1106.

PMID: 38724164 PMC: 11493333. DOI: 10.1016/j.jaip.2024.03.021.

Recombinant human diamine oxidase prevents hemodynamic effects of continuous histamine infusion in guinea pigs.

Weiss-Tessbach M, Reiter B, Gludovacz E, Boehm T, Jilma B, Rager-Resch M Inflamm Res. 2023; 72(10-11):2013-2022.

PMID: 37812220 PMC: 10611646. DOI: 10.1007/s00011-023-01783-3.

Immediate hypersensitivity reactions to iodinated contrast media: The diagnosis of allergy by skin testing.

Caron J, Graf S, Delebarre-Sauvage C Clin Transl Allergy. 2022; 12(12):e12214.

PMID: 36573311 PMC: 9720225. DOI: 10.1002/clt2.12214.

Bridging the gap between bench and clinic: the importance of understanding the mechanism of iodinated contrast media hypersensitivity.

Sullivan C, Paul N, Rieder M Br J Radiol. 2022; 96(1141):20220494.

PMID: 36395475 PMC: 10997019. DOI: 10.1259/bjr.20220494.

References

Lieberman P, Seigle R . Reactions to radiocontrast material. Anaphylactoid events in radiology. Clin Rev Allergy Immunol. 2000; 17(4):469-96. DOI: 10.1007/BF02737651. View

Glas A, Lijmer J, Prins M, Bonsel G, Bossuyt P . The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56(11):1129-35. DOI: 10.1016/s0895-4356(03)00177-x. View

Johansson S, Bieber T, Dahl R, Friedmann P, Lanier B, Lockey R . Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113(5):832-6. DOI: 10.1016/j.jaci.2003.12.591. View

Brockow K, Christiansen C, Kanny G, Clement O, Barbaud A, Bircher A . Management of hypersensitivity reactions to iodinated contrast media. Allergy. 2005; 60(2):150-8. DOI: 10.1111/j.1398-9995.2005.00745.x. View

Kvedariene V, Martins P, Rouanet L, Demoly P . Diagnosis of iodinated contrast media hypersensitivity: results of a 6-year period. Clin Exp Allergy. 2006; 36(8):1072-7. DOI: 10.1111/j.1365-2222.2006.02532.x. View

Hasdenteufel F, Luyasu S, Renaudin J, Paquay J, Carbutti G, Beaudouin E . Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment. J Allergy Clin Immunol. 2007; 121(2):527-8. DOI: 10.1016/j.jaci.2007.08.027. View

Trcka J, Schmidt C, Seitz C, Brocker E, Gross G, Trautmann A . Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy?. AJR Am J Roentgenol. 2008; 190(3):666-70. DOI: 10.2214/AJR.07.2872. View

Bohm I, Schild H . Contrast-media-induced hypersensitivity or allergic/allergic-like reactions? Suggestion for a more appropriate use of the nomenclature. Eur J Clin Pharmacol. 2008; 64(9):931-2. DOI: 10.1007/s00228-008-0527-1. View

Brockow K, Romano A, Aberer W, Bircher A, Barbaud A, Bonadonna P . Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy. 2009; 64(2):234-41. DOI: 10.1111/j.1398-9995.2008.01832.x. View

10.

Galera C, Pur Ozygit L, Cavigioli S, Bousquet P, Demoly P . Gadoteridol-induced anaphylaxis - not a class allergy. Allergy. 2009; 65(1):132-4. DOI: 10.1111/j.1398-9995.2009.02137.x. View

11.

Dewachter P, Laroche D, Mouton-Faivre C, Bloch-Morot E, Cercueil J, Metge L . Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol. 2009; 77(3):495-501. DOI: 10.1016/j.ejrad.2009.09.019. View

12.

Prince M, Zhang H, Zou Z, Staron R, Brill P . Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011; 196(2):W138-43. DOI: 10.2214/AJR.10.4885. View

13.

Goksel O, Aydin O, Atasoy C, Akyar S, Demirel Y, Misirligil Z . Hypersensitivity reactions to contrast media: prevalence, risk factors and the role of skin tests in diagnosis--a cross-sectional survey. Int Arch Allergy Immunol. 2011; 155(3):297-305. DOI: 10.1159/000320760. View

14.

Valent P, Akin C, Arock M, Brockow K, Butterfield J, Carter M . Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2011; 157(3):215-25. PMC: 3224511. DOI: 10.1159/000328760. View

15.

Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K . Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990; 175(3):621-8. DOI: 10.1148/radiology.175.3.2343107. View

16.

Brockow K, Garvey L, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo M . Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013; 68(6):702-12. DOI: 10.1111/all.12142. View

17.

Prieto-Garcia A, Tomas M, Pineda R, Tornero P, Herrero T, Fuentes V . Skin test-positive immediate hypersensitivity reaction to iodinated contrast media: the role of controlled challenge testing. J Investig Allergol Clin Immunol. 2013; 23(3):183-9. View

18.

Salas M, Gomez F, Fernandez T, Dona I, Aranda A, Ariza A . Diagnosis of immediate hypersensitivity reactions to radiocontrast media. Allergy. 2013; 68(9):1203-6. DOI: 10.1111/all.12214. View

19.

Kim M, Lee S, Lee S, Yang M, Jung J, Park C . Anaphylaxis to iodinated contrast media: clinical characteristics related with development of anaphylactic shock. PLoS One. 2014; 9(6):e100154. PMC: 4059752. DOI: 10.1371/journal.pone.0100154. View

20.

McNeil B, Pundir P, Meeker S, Han L, Undem B, Kulka M . Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2014; 519(7542):237-41. PMC: 4359082. DOI: 10.1038/nature14022. View